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Specific proinflammatory alleles are associated with higher risk of Alzheimer disease (AD) in diﬀerent onset age. The homozygosis
for the A allele of−1082 polymorphism (G/A) of interleukin-10 (IL-10) promotes a higher risk of AD and reduced IL-10 generation
in peripheral cells after amyloid stimulation. In this paper we analysed genotype and allele frequencies of this polymorphism in
138 subjects with mild cognitive impairment (MCI) diagnosed, respectively, as amnestic (a-MCI) and multiple impaired cognitive
domains (mcd-MCI). The genotype frequencies were similar in a-MCI and AD subjects, whereas in mcd-MCI comparable to
controls (AA genotype: 50% in a-MCI, 49.2% in AD, 28.7% in mcd-MCI and 31.8% in controls). Consequently, both allele and
genotype distributions were significantly diﬀerent between a-MCI and mcd-MCI (allele: P = .02, genotype: P < .05). These results
support the theory that polymorphisms of cytokine genes can aﬀect neurodegeneration and its clinical progression. IL-10 may
partly explain the conversion of a-MCI to AD or be a genetic marker of susceptibility.
1. Introduction
The pathogenic process of Alzheimer’s disease (AD) starts
decades before the clinical onset of the disease [1]. During
this preclinical phase, there is a gradual loss of axons and
neurons, and at a certain threshold the first symptoms,
most often impaired episodic memory, appear. At this stage,
patients do not fulfil the criteria for dementia and may be
diagnosed with mild cognitive impairment (MCI). There is
considerable clinical heterogeneity of this pathology since
diﬀerent clinical patterns can be recognized: amnestic MCI
(a-MCI), MCI with multiple impaired cognitive domains
(mcd-MCI), and single nonmemory domain MCI [2].
Although a-MCI may be the preclinical stage of AD, there
is no established method to predict progression to AD in
individuals with MCI.
Inflammation is accepted to be a feature of AD [3, 4]
and the pathogeneses of neurodegeneration have been at
least in part attributed to the release of proinflammatory
cytokines from brain resident cells [5, 6] and, although
less consistently, from peripheral cell [7, 8]. Furthermore,
an increased intrathecal production of the proinflammatory
cytokine TNF-α and a decreased production of the anti-
inflammatory cytokine TGF-β have been demonstrated in
the brain of patients with MCI, suggesting there is a
proinflammatory state in such patients at high risk for AD
[9].
Moreover, circulating acute phase reactant levels in
middle age predict AD risk in old age and in particular cer-
tain functional promoter polymorphisms in cognate genes
that modulate inflammation are often found at elevated
frequency among AD cases.
Recently specific risk sets of proinflammatory alleles were
identified that characterize AD in diﬀerent onset age (before
age 65, at ages 65–74, and at older ages) [10].
These alleles comprise also the −1082 promoter gene
polymorphisms of IL-10 (G/A substitution) [11].
IL-10 maps to chromosome 1 between 1q31 and 1q32
is highly polymorphic, and its production is correlated
to biallelic polymorphisms at positions −1082 (G to A),
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−819 (T to C), and −592 (A to C). The polymorphism at
position −1082 lies within an Ets (E-twenty-six specific)-
like recognition site and may aﬀect the binding of this
transcriptional factor and, therefore, alter transcription
activation; the −1082 A allele correlates with low IL-10
generation after stimulation of T cells in vitro [12], while
polymorphisms at positions −819 and −592 do not seem to
be involved.
In a previous study, we found that the homozygosis for
the A allele of the IL-10 −1082 G/A single nucleotide poly-
morphism (SNP) was associated with six-fold higher risk of
AD. In the same study, we also analysed the production of IL-
10 in Peripheral Blood Mononuclear Cells (PBMCs) of AD
patients and age-matched controls after specific stimulation
with amyloid peptide, LPS, and Flu. Since the generation
of IL-10 was reduced in patients after amyloid stimulation,
we concluded that these specific immune responses may be
selectively impaired in AD [13].
The aim of this study was to analyse the genotype and
allele frequencies of these IL-10 SNPs in 138 subjects with
MCI and to compare them with those previously shown in
AD and healthy controls (HCs) [13].
2. Materials and Methods
2.1. Study Protocol. This study comprised 138 subjects with
MCI age 80.37 ± 5.93 years (mean ± standard deviation
(SD)). All patients were Caucasian, living in Northern
Italy, and selected from a larger ambulatory population
sample followed at the Geriatric Unit of the Ospedale
Maggiore Policlinico IRCCS, University of Milan, Italy and
the Geriatric Clinic of the University of Milan-Bicocca, Italy.
At enrolment,MCI subjects were divided into two groups
based on cognitive features and diagnosed, respectively, as a-
MCI (30 patients) and mcd-MCI (108 patients).
In particular, a-MCI met the criteria described by
Petersen [14]: subjects with memory impairment only
(>1.5 SD above the age- and education-specific norms) and
no diﬃculties in any other area of cognitive functions.
mcd-MCIs were subjects diagnosed with impairment in
at least two cognitive domains of more than 1 SD below
the mean of the respective age- and education-matched
population, and with cognitive decline confirmed by the
individuals themselves or reliable informants, but in whom
no diagnosis of dementia could be achieved. A cut-oﬀ score
of 1 SD was applied, which is less severe than that used
for a-MCI, in order to obtain higher diagnostic sensitivity
even though diagnostic specificity was reduced. Because the
presence of more than one cognitive deficit and frequently
initial impairment in Lawton’s instrumental activities of daily
living also characterized mcd-MCI, it may be mistaken for
dementia; thus, a less severe criterion (>1 SD) allows better
diﬀerentiation between mcd-MCI and dementia [15].
At this time, 74 patients out of the 138 completed a
four-year follow-up and 24 were diagnosed with AD, 22
with vascular dementia (MCI→VD), and 28 with stable
MCI [16]. Subjects who developed AD during follow-up
were required to meet the DSM IV (Diagnostic and Statis-
tical Manual of mental Disorders—4th ed.) and NINCDS-
ADRDA (National Institute of Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disorders Asso-
ciation Work Group) criteria [17].
Within MCI who progressed to AD (MCI→AD), only
two were diagnosed as mcd-MCI at enrolment; all the others
were diagnosed as a-MCI.
In order to minimize the risk of possible inflammatory
processes, all subjects were selected in the absence of clinical
signs of inflammation (e.g., normal body temperature, no
concomitant inflammatory condition) and with normal
blood chemistry (red blood cell sedimentation rate, albumin,
transferring, and C reactive protein plasma levels).
Informed consent was obtained from all subjects and
the Ethics Committee of both universities approved the
study, which was conducted according to the Helsinki II
declaration. This population was matched with AD patients
(n = 63) and nonsdemented sex- and age-matched healthy
controls (n = 63) enrolled for our previous study [13].
2.2. Gene Polymorphism Analysis. Whole blood was collected
by venipuncture in Vacutainer tubes containing EDTA
(Becton Dickinson Co., Rutherford, NJ).
Genomic DNA was extracted by the salting-out method
as described in [18]. The concentration and purity of DNA
were determined by spectrophotometric analysis. In order to
establish IL-10 genotypes we employed a polymerase chain
reaction using sequence-specific primers (PCR-SSPs). The
sequence in the promoter region of the IL-10 gene (polymor-
phic positions −1082, −819, and −592) was amplified using
the cytokine genotyping tray method (One Lambda, Canoga
Park, CA, USA). The human β-globin gene was amplified
as an internal control for the genomic DNA preparation.
PCR conditions were indicated by the One Lambda PCR
program (OLI-1) and the PCR products were visualised by
electrophoresis in 2.5% agarose gel.
ApoE genotypes were determined by means of PCR
amplification of a 234 base-pair fragment of exon 4 of
the ApoE gene, followed by digestion with Cfo1. The
restriction patterns were revealed by means of 4% agarose
gel electrophoresis [13].
2.3. Statistical Analysis. Statistical analysis was performed
with the SPSS statistical package (SPSS version 17, Chicago,
IL). Genotype and allele frequencies in the study groups were
compared using the χ2-test. P < .05 was taken as the cut-oﬀ
for statistical significance.
3. Results
3.1. Distribution of IL-10 Genotypes in MCI Subjects. The
genotype and allele frequencies of the biallelic polymor-
phism at position −1082 are reported in Table 1. This
SNP alters transcriptional activation with a gene dosage-
related eﬀect, so GG genotype correlates with high, GA
with intermediate, and AA with low IL-10 production after
stimulation of T cells in vitro [12].
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Table 1: Distribution of genotype and allele frequencies of −1082 (G/A) SNP in Alzheimer’s disease patients (AD), control subjects (CT),
and mild cognitive impairment patients (MCI).
GG (H) GA (M) AA (L) G A
AD 4 (6.4%) 28 (44.4%) 31 (49.2%) 36 (28.6%) 90 (71.4%)
CT 14 (22.2%) 29 (46%) 20 (31.8%) 57 (45.2%) 69 (54.8%)
MCI 21 (15.2%) 71 (51.4%) 46 (33.3%) 113 (40.9%) 163 (59.1%)
Genotype: χ2 9.480, d.f. 4; P = .05.
Allele: χ2 8.257, d.f. 2; P = .02.
Table 2: Distribution of genotype and allele frequencies of −1082 (G/A) SNP in amnestic MCI (a-MCI) and multiple cognitive domains
MCI patients (mcd-MCI).
GG (H) GA (M) AA (L) G A
a-MCI 1 (3.3%) 14 (46.7%) 15 (50%) 16 (26.7%) 44 (73.3%)
mcd-MCI 20 (18.5%) 57 (52.8%) 31 (28.7%) 97 (44.9%) 119 (55.1%)
Genotype: χ2 6.927, d.f. 2; P < .05.
Allele: χ2 5.729, d.f. 1; P = .02.
Table 3: Distribution of genotype and allele frequencies of −1082 (G/A) SNP in MCIs that remain stable, progressed to AD (MCI→AD),
and progressed to VD (MCI→VD).
GG (H) GA (M) AA (L) G A
MCI stable 8 (28.6%) 12 (42.8%) 8 (28.6%) 28 (50%) 28 (50%)
MCI→AD 2 (8.3%) 12 (50%) 10 (41.7%) 16 (33.3%) 32 (66.7%)
MCI→VD 5 (22.7%) 11 (50%) 6 (27.3%) 21 (47.7%) 23 (52.3%)
Genotype distribution compared percentages: χ2 15.604, d.f. 4; P = .004.
Allele distributions compared percentages: χ2 6.661, d.f. 2; P < .05.
As previously described [13], AD patients show a signif-
icant higher frequency of the −1082A low producer allele,
which skews the genotype distribution in AD compared to
HC, with a significant decrease of −1082 GG high producer
genotype.
MCI subjects as a whole had an intermediate pattern
between AD and HC subjects, the percentages of G allele and
GG genotype being 40.9% and 15.2%, while the percentage
of A allele and AA genotype being 59.1% and 33.3%,
respectively, (allele: P = .02, genotype: P = .05) (Table 1).
It is interesting to note that the genotype frequencies of
the −1082 SNP in a-MCI subjects were similar to those of
AD subjects, whereas those of mcd-MCI were comparable
to HC (AA genotype 50% in a-MCI and 49.2% in AD;
28.7% and 31.8% in mcd-MCI and HC, resp.) (Table 2).
Consequently, the allele and genotype distributions were
significantly diﬀerent between a-MCI and mcd-MCI (allele:
P = .02, genotype: P < .05).
The same SNP is linked with two other SNPs at positions
−819 and −592. They combine with microsatellite alleles to
form haplotypes where the diﬀerence in IL-10 production
is mainly accounted by the −1082 SNP [19, 20]. The
genotype and allele frequencies of−819 and−592 SNPs were
distributed similarly in our samples (data not shown).
3.2. Distribution of Apolipoprotein E Genotype in MCI
Subjects. The frequency of ApoE ε4 in our sample was in
line with the data already published [21–24]. In particular
genotyping of our MCI patients globally considered revealed
the presence of ε4 allele in 40% of cases and, during follow-
up, in 54% ofMCI→AD and 39% in stable MCI. The ApoE4
status is an independent risk factor for AD [13].
3.3. Follow-Up. After a 4-year follow-up 24 MCI progressed
to AD (MCI→AD) [16] and 22 progressed to vascular
dementia (MCI→VD). Table 3 shows −1082 SNP distribu-
tions in MCI progressing and not progressing to AD (stable
MCI).
In MCI→AD both A allele and AA genotype were higher
than in stable MCI and in MCI→VD.
Due to the limited number of patients that completed
the follow-up period, the data reached the statistical signifi-
cances only comparing genotype and allele percentage (allele:
P < .05, genotype P = .004).
4. Discussion
A “cytokine cycle” has been proposed where [25] the
anti-inflammatory cytokines (IL-4, IL-10, and IL-13) reg-
ulate β-amyloid-induced microglial/macrophage inflamma-
tory responses and modify the microglial activity sur-
rounding amyloid neuritic plaques [26]. These cytokines
can inhibit the induction of IL-1, TNF-α, and MCP-1
in diﬀerentiated human monocytes and, above all, IL-
10 causes dose-dependent inhibition of the IL-6 secretion
induced by β-amyloid in these cells and in murine microglia
[25].
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In a previous paper, we described not only a significantly
higher percentage of IL-10 −1082 AA low-producing geno-
type among AD cases, but also a reduced IL-10 generation in
peripheral blood mononuclear cells from these patients after
β-amyloid stimulation [13].
Interestingly a report on Italian centenarians, who are
clearly less prone than younger persons to age-related
diseases, showed that extreme longevity is significantly
associated with the high IL-10-producing genotypes [27].
In the present study, the allele frequencies of −1082 SNP
in a-MCI subjects were similar to those of AD patients,
whereas those of mcd-MCI were comparable to HC (the
frequencies of the low-producer AA genotype were 50% and
28.7%, in a-MCI and mcd-MCI, resp.).
It is to note that, after an adequate period of follow-
up, the twenty-four a-MCI subjects that progressed to AD
showed a higher percentage of AA carriers (41.7%) compared
to those of MCI that remain stable (28.6%) and compared to
those progressed in vascular dementia (27.3%). The similar
genotype distribution of this IL-10 SNP in AD and a-MCI
but not in mcd-MCI and the data retrospectively obtained
after the follow-up suggest that it is potentially involved in
the conversion of a-MCI to AD.
However, our results support the theory that the overall
risk of developing AD may be governed by a multifactorial
“susceptibility profile” and that polymorphisms of cytokine
genes can aﬀect neurodegeneration and its clinical progres-
sion.
In addiction, IL-10 may partly explain the conversion of
a-MCI to AD or, at least, be a genetic marker of susceptibility
[28].
Therefore, it is extremely relevant to closely define
intrinsic (i.e., genetic) individual risk profiles in prevention
and treatment trials. The finding that the set of gene variants
in innate immunity associated with earlier onset predicted
rapid clinical progression suggests that interventions to
control inflammation might be useful especially for relatively
younger cases to delay disease progression.
References
[1] J. L. Price and J. C. Morris, “Tangles and plaques in nonde-
mented aging and “preclinical” Alzheimer’s disease,” Annals of
Neurology, vol. 45, no. 3, pp. 358–368, 1999.
[2] R. C. Petersen, R. Doody, A. Kurz et al., “Current concepts in
mild cognitive impairment,” Archives of Neurology, vol. 58, no.
12, pp. 1985–1992, 2001.
[3] H. W. Querfurth and F. M. LaFerla, “Alzheimer’s disease,” The
New England Journal of Medicine, vol. 362, no. 4, pp. 329–344,
2010.
[4] T. Wyss-Coray, “Inflammation in Alzheimer disease: driving
force, bystander or beneficial response?” Nature Medicine, vol.
12, no. 9, pp. 1005–1015, 2006.
[5] E. Tarkowski, K. Blennow, A. Wallin, and A. Tarkowski,
“Intracerebral production of tumor necrosis factor-α, a local
neuroprotective agent, in Alzheimer disease and vascular
dementia,” Journal of Clinical Immunology, vol. 19, no. 4, pp.
223–230, 1999.
[6] E. Tarkowski, A.-M. Liljeroth, A˚. Nilsson, L. Minthon, and
K. Blennow, “Decreased levels of intrathecal interleukin 1
receptor antagonist in Alzheimer’s disease,” Dementia and
Geriatric Cognitive Disorders, vol. 12, no. 5, pp. 314–317, 2001.
[7] P. Bermejo, S. Martı´n-Arago´n, J. Benedı´ et al., “Diﬀerences
of peripheral inflammatory markers between mild cognitive
impairment and Alzheimer’s disease,” Immunology Letters, vol.
117, no. 2, pp. 198–202, 2008.
[8] K. Bonotis, E. Krikki, V. Holeva, C. Aggouridaki, V. Costa, and
S. Baloyannis, “Systemic immune aberrations in Alzheimer’s
disease patients,” Journal of Neuroimmunology, vol. 193, no. 1-
2, pp. 183–187, 2008.
[9] S. Ray, M. Britschgi, C. Herbert et al., “Classification and
prediction of clinical Alzheimer’s diagnosis based on plasma
signaling proteins,” Nature Medicine, vol. 13, no. 11, pp. 1359–
1362, 2007.
[10] F. Licastro, E. Porcellini, C. Caruso, D. Lio, and E. H. Corder,
“Genetic risk profiles for Alzheimer’s disease: integration of
APOE genotype and variants that up-regulate inflammation,”
Neurobiology of Aging, vol. 28, no. 11, pp. 1637–1643, 2007.
[11] D. Lio, F. Licastro, L. Scola et al., “Interleukin-10 promoter
polymorphism in sporadic Alzheimer’s disease,” Genes and
Immunity, vol. 4, no. 3, pp. 234–238, 2003.
[12] J. M. Kim, C. I. Brannan, N. G. Copeland, N. A. Jenkins, T.
A. Khan, and K. W. Moore, “Structure of the mouse IL-10
gene and chromosomal localization of the mouse and human
genes,” Journal of Immunology, vol. 148, no. 11, pp. 3618–3623,
1992.
[13] B. Arosio, D. Trabattoni, L. Galimberti et al., “Interleukin-
10 and interleukin-6 gene polymorphisms as risk factors for
Alzheimer’s disease,” Neurobiology of Aging, vol. 25, no. 8, pp.
1009–1015, 2004.
[14] R. C. Petersen, “Mild cognitive impairment as a diagnostic
entity,” Journal of Internal Medicine, vol. 256, no. 3, pp. 183–
194, 2004.
[15] M. Zanetti, C. Ballabio, C. Abbate, C. Cutaia, C. Vergani,
and L. Bergamaschini, “Mild cognitive impairment subtypes
and vascular dementia in community-dwelling elderly people:
a 3-year follow-up study,” Journal of the American Geriatrics
Society, vol. 54, no. 4, pp. 580–586, 2006.
[16] O. Hansson, H. Zetterberg, P. Buchhave, E. Londos,
K. Blennow, and L. Minthon, “Association between CSF
biomarkers and incipient Alzheimer’s disease in patients
with mild cognitive impairment: a follow-up study,” Lancet
Neurology, vol. 5, no. 3, pp. 228–234, 2006.
[17] G. McKhann, D. Drachman, and M. Folstein, “Clinical diag-
nosis of Alzheimer’s disease: report of the NINCDS-ADRDA
work group under the auspices of Department of Health
and Human Services Task Force on Alzheimer’s disease,”
Neurology, vol. 34, no. 7, pp. 939–944, 1984.
[18] S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting
out procedure for extracting DNA from human nucleated
cells,” Nucleic Acids Research, vol. 16, no. 3, p. 1215, 1988.
[19] J. Eskdale, P. Wordsworth, S. Bowman, M. Field, and G. Gal-
lagher, “Association between polymorphisms at the human IL-
10 locus and systemic lupus erythematosus,” Tissue Antigens,
vol. 49, no. 6, pp. 635–639, 1997.
[20] J. Eskdale, G. Gallagher, C. L. Verweij, V. Keijsers, R. G. J.
Westendorp, and T. W. J. Huizinga, “Interleukin 10 secretion
in relation to human IL-10 locus haplotypes,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 95, no. 16, pp. 9465–9470, 1998.
[21] D. J. Berlau, M. M. Corrada, E. Head, and C. H. Kawas, “ApoE
ε2 is associated with intact cognition but increased Alzheimer
pathology in the oldest old,” Neurology, vol. 72, no. 9, pp. 829–
834, 2009.
International Journal of Alzheimer’s Disease 5
[22] G. Bu, “Apolipoprotein E and its receptors in Alzheimer’s
disease: pathways, pathogenesis and therapy,” Nature Reviews
Neuroscience, vol. 10, no. 5, pp. 333–344, 2009.
[23] P. P. Singh, M. Singh, and S. S. Mastana, “APOE distribution
in world populations with new data from India and the UK,”
Annals of Human Biology, vol. 33, no. 3, pp. 279–308, 2006.
[24] J. Kim, J. M. Basak, and D. M. Holtzman, “The role of
apolipoprotein E in Alzheimer’s disease,” Neuron, vol. 63, no.
3, pp. 287–303, 2009.
[25] A. M. Szczepanik, S. Funes, W. Petko, and G. E. Ringheim,
“IL-4, IL-10 and IL-13 modulate Aβ(1-42)-induced cytokine
and chemokine production in primary murine microglia and
a human monocyte cell line,” Journal of Neuroimmunology,
vol. 113, no. 1, pp. 49–62, 2001.
[26] C. C. Chao, T. W. Molitor, and S. Hu, “Neuroprotective role of
IL-4 against activated microglia,” Journal of Immunology, vol.
151, no. 3, pp. 1473–1481, 1993.
[27] D. Lio, L. Scola, A. Crivello et al., “Gender-specific asso-
ciation between—1082 IL-10 promoter polymorphism and
longevity,” Genes and Immunity, vol. 3, no. 1, pp. 30–33, 2002.
[28] O. Combarros, P. Sa´nchez-Juan, J. A. Riancho et al., “Aro-
matase and interleukin-10 genetic variants interactively mod-
ulate Alzheimer’s disease risk,” Journal of Neural Transmission,
vol. 115, no. 6, pp. 863–867, 2008.
